BioStock: Fast Track designation facilitates development of Oncoinvent’s Radspherin
The FDA has granted Fast Track to Oncoinvent for its radiopharmaceutical Radspherin as a treatment for peritoneal metastases originating from ovarian cancer. This designation will facilitate the candidate’s clinical development, with the next step being a phase IIb trial first in ovarian cancer patients, then in colorectal cancer patients.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se